| furosemide / Generic mfg. |
NCT00652782: Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure Patients |
|
|
| Completed | 2 | 160 | US | rolofyline, MK7418, Comparator Placebo (unspecified) | NovaCardia, Inc., Merck Sharp & Dohme LLC | Congestive Heart Failure, Renal Impairment | 08/05 | | | |
NCT00283361: ZP120 Add-on to Furosemide in Treatment of Acute or Sub-Acute Decompensated Heart Failure |
|
|
| Terminated | 2 | 130 | US | ZP120, I.v. catherization, 6-minutes walk performance, Dyspnea severity assessment, Blood sampling for laboratory tests, ECG, Physical examination | Zealand Pharma, Syneos Health | Heart Failure, Congestive | | 12/06 | | |
| Completed | 2 | 33 | US | Diuresis (furosemide) part I, Fluid Bolus (crystalloid or albumin), Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine), Dobutamine, Concentrate all drips and nutrition, Diuresis (furosemide) part II, Dialysis | Oregon Health and Science University, Pulsion Medical Systems, Oregon Clinical and Translational Research Institute | Acute Lung Injury | 01/11 | 01/11 | | |
NCT01125514 / 2008-006156-22: A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure |
|
|
| Completed | 2 | 37 | Europe | Aliskiren 150 mg, Furosemide 60 mg, Placebo for Aliskiren, Aliskiren 300 mg | Novartis Pharmaceuticals | Heart Failure | 08/11 | 08/11 | | |
| Ongoing | 2 | 32 | Europe | Ionic Contra-Viral Therapy (ICVT) comprised of digoxin and furosemide, CLS003, Gel | Cutanea Life Sciences, Cutanea Life Sciences | Actinic keratosis, Actinic keratosis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2016-000870-39: Digoxin / Furosemide topical therapy for genital warts and VIN lesions of immunocompromised and immunocompetent patients |
|
|
| Not yet recruiting | 2 | 48 | Europe | Ionic Contra-Viral Therapy (ICVT) comprised of digoxin and furosemide, CLS003, Gel | Cutanea Life Sciences, Cutanea Life Science | HPV-induced genital lesions of immunocompromised and immunocompetent patients, Genital warts or Vulval HSIL, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT03684772: Topical Ionic Contra-Viral Therapy in Actinic Keratosis |
|
|
| Unknown status | 2 | 32 | Europe | ICVT Topical Gel, Furosemide Topical Gel, Digoxin Topical Gel, Vehicle Topical Gel | Maruho Co., Ltd. | Actinic Keratosis | 09/19 | 09/19 | | |
NCT02527798: Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD) |
|
|
| Completed | 2 | 82 | US | Furosemide Cohort 1, Lasix, Furosemide Cohort 2, Furosemide Cohort 3, Placebo, sugar water | University of North Carolina, Chapel Hill, Duke University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), The Emmes Company, LLC | Bronchopulmonary Dysplasia | 10/19 | 10/19 | | |
NCT03730961: An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic |
|
|
| Completed | 2 | 23 | Europe | BMS-986231, Furosemide, Placebo | Bristol-Myers Squibb | Cardiac Failure, Myocardial Failure, Congestive Heart Failure, Heart Decompensation | 12/19 | 01/20 | | |
2018-000970-31: A study designed to evaluate the effects of BMS-986231 versus placebo on urine output when taken with a single dose of a diuretic (furosemide). BMS-986231 or Placebo are provided in the form of Intravenous Infusions for a duration of 8 hours, with furosemide given after 4 hours, in patients whose heart is unable to pump sufficiently (chronic heart failure); exposed to each of the 2 interventions over the course of the study. |
|
|
| Not yet recruiting | 2 | 20 | Europe | BMS-986231-01 for Injection, 240 mg/vial, BMS-986231, Powder for concentrate for solution for infusion | Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb International Corporation | Heart failure with reduced ejection fraction (HFrEF), Inability of the heart to pump sufficiently to maintain blood flow to meet the body's needs., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Completed | 2 | 482 | Europe, RoW | BAY 1753011, Placebo BAY 1753011, Furosemide, Placebo Furosemide | Bayer | Heart Failure (HF) | 04/21 | 05/21 | | |
NCT04496596: Study of Suramin in Subjects With Furosemide-Resistant AKI |
|
|
| Active, not recruiting | 2 | 68 | US | Suramin, Placebo | Rediscovery Life Sciences | Acute Kidney Injury | 04/23 | 12/23 | | |
NCT05779943: Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer |
|
|
| Active, not recruiting | 2 | 20 | US | Furosemide, 54-31-9, FRS, Furosemide, FUROSEMIDE, Lasix, Lasix, LB 502, LB-502, LB-502, SK-Furosemide, F18-rhPSMA-7.3, (18F)-rhPSMA-7.3,18F-rhPSMA-7.3,18FrhPSMA-7.3,2305081-64-3,F-18-rhPSMA-7.3,FLOTUFOLASTAT F-18, Fluorine F18 radiohybrid PSMA-7.3, Fluorine F18 rhPSMA-7.3, Fluorine-18 rhPSMA-7.3, rhPSMA-7.3(18F), Positron Emission Tomography, Medical Imaging,Positron Emission Tomography, PET, PET SCAN, Computed Tomography, CAT, CAT Scan, CAT scan, CAT Scan,Computed Axial Tomography,Computed Tomography, Computerized Axial Tomography | Emory University, National Cancer Institute (NCI), Blue Earth Diagnostics | Prostate Adenocarcinoma, Recurrent Prostate Carcinoma | 07/27 | 07/28 | | |
| Completed | 1/2 | 10 | Europe | Furosemide injection solution for subcutaneous administration (80 mg), Oral Furosemide tablets (80 mg) | scPharmaceuticals, Inc. | Heart Failure | 06/15 | 06/15 | | |
NCT01756677: Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients |
|
|
| Active, not recruiting | 1/2 | 24 | US | Cytarabine, Cytosar, Ara-C, DepoCyt, Cytosine arabinosine hydrochloride, Low dose Ara-C, LDAC, Lintuzumab-Ac225, Lintuzumab, Lasix, furosemide, Spironolactone | M.D. Anderson Cancer Center, Actinium Pharmaceuticals | Leukemia | 10/16 | | | |
|
|
| Withdrawn | 1/2 | 0 | US | Furosemide Injection Solution 8mg/mL, SCP-101, Buffered Lasix, Buffered furosemide | Todd M Koelling, MD, scPharmaceuticals, Inc. | Acute Decompensated Heart Failure | 03/17 | 03/17 | | |
NCT02575963: Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients |
|
|
| Completed | 1/2 | 40 | US | Cytarabine (Phase 1 only), Low dose Ara-C, LDAC, Lintuzumab-Ac225, HuM195-Ac225, Actimab-A, Furosemide (Phase 1 only), Lasix, Spironolactone, Aldactone | Actinium Pharmaceuticals | AML | 11/18 | 05/20 | | |
|
|
|
NCT04384653: Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure |
|
|
| Completed | 1/2 | 20 | US | Furosemide Injection Solution for subcutaneous administration (80 mg), Furosemide Injection, USP, Medfusion 3500 (v6) precision infusion pump | SQ Innovation, Inc., Accel Clinical Services | Heart Failure | 06/21 | 06/21 | | |
| Not yet recruiting | 1/2 | 84 | Europe | PolyCore (Polydextrin, L-Carnitine, D-xylitol), PolyCore peritoneal dialysis solution | Iperboreal Pharma Srl | Congestive Heart Failure | 11/25 | 03/26 | | |
